Polycystic Ovarian Syndrome: the Next Cardiovascular Dilemma in Women?

Endocrinology and Metabolism Clinics of North America

Volumn 35, Issue 3, 2006, Pages 611-631

  Srikanthan, Preethi ^a   Korenman, Stanley ^a   Davis, Susan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ANDROGEN; ANTIANDROGEN; C REACTIVE PROTEIN; CARBOHYDRATE; CYPROTERONE; DIANE; DIAZOXIDE; ESTROGEN; ETHINYLESTRADIOL; FOLIC ACID; GESTAGEN; GONADOTROPIN; HOMOCYSTEINE; INSULIN; METFORMIN; METHYLTESTOSTERONE; ORAL CONTRACEPTIVE AGENT; ROSIGLITAZONE; TROGLITAZONE; VITAMIN B GROUP;

BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE MARKER; DISEASE PREDISPOSITION; DYSLIPIDEMIA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOTHELIAL DYSFUNCTION; GENETIC PREDISPOSITION; HUMAN; HYPERANDROGENISM; HYPERHOMOCYSTEINEMIA; HYPERINSULINEMIA; HYPERPROLACTINEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; KINESIOTHERAPY; LONGITUDINAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

BLOOD COAGULATION DISORDERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; HYPERLIPIDEMIAS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; OBESITY; POLYCYSTIC OVARY SYNDROME; RISK FACTORS;

EID: 33748298876     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2006.05.001     Document Type: Review

References (112)

1. Knochenhauer E. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83 (1998) 3078-3082
2. Azziz R., Woods K.S., Reyna R., et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89 (2004) 2745-2749
3. Stein I.F., and Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29 (1935) 181-191
4. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19 (2004) 41-47
5. Morley J.E., Patrick P., and Perry III H.M. Evaluation of assays available to measure free testosterone. Metabolism 51 (2002) 554-559
6. Carmina E., Chu M.C., Longo R.A., et al. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 90 (2005) 2545-2549
7. Balen A.H., Laven J.S., Tan S.L., et al. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 9 (2003) 505-514
8. Ehrmann D.A., Barnes R.B., and Rosenfield R.L. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 16 (1995) 322-353
9. Ehrmann D.A., Rosenfield R.L., Barnes R.B., et al. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 327 (1992) 157-162
10. Rosenfield R.L. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am 28 (1999) 265-293
11. Legro R.S., and Strauss J.F. Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 78 (2002) 569-576
12. Plymate S.R., Hoop R.C., Jones R.E., et al. Regulation of sex hormone-binding globulin production by growth factors. Metabolism 39 (1990) 967-970
13. Silfen M.E., Denburg M.R., Manibo A.M., et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 88 (2003) 4682-4688
14. Conway G. Heterogeneity in the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol (Oxf) 30 (1989) 459-470
15. Nestler J.E., Barlascini C.O., Matt D.W., et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 68 (1989) 1027-1032
16. Toscano V. Lack of linear relationship between hyperinsulinemia and hyperandrogenism. Clin Endocrinol (Oxf) 36 (1992) 197-202
17. Nelson V.L., Qin Kn K.N., Rosenfield R.L., et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 86 (2001) 5925-5933
18. Legro R.S., and Strauss J.F. Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 78 (2002) 569-576
19. Ferriman D., and Purdie A.W. The inheritance of polycystic ovarian disease and a possible relationship to premature balding. Clin Endocrinol (Oxf) 11 (1979) 291-300
20. Falcone T., Finegood D.T., Fantus I.G., et al. Androgen response to endogenous insulin secretion during the frequently sampled intravenous glucose tolerance test in normal and hyperandrogenic women. J Clin Endocrinol Metab 71 (1990) 1653-1657
21. Rajaniemi H.J., Ronnberg L., Kauppila A., et al. Luteinizing hormone receptors in ovarian follicles of patients with polycystic ovarian disease. J Clin Endocrinol Metab 51 (1980) 1054-1057
22. Cataldo N.A. Insulin-like growth factor binding proteins: do they play a role in polycystic ovary syndrome?. Semin Reprod Endocrinol 15 (1997) 123-136
23. Imse V., Holzapfel G., Hinney B., et al. Comparison of luteinizing hormone pulsatility in the serum of women suffering from polycystic ovarian disease using a bioassay and five different immunoassays. J Clin Endocrinol Metab 74 (1992) 1053-1061
24. Azziz R., Ehrmann D., Legro R.S., et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86 (2001) 1626-1632
25. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289 (2003) 76-79
26. Evans D.J., Hoffmann R.G., Kalkhoff R.K., et al. Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women. J Clin Endocrinol Metab 57 (1983) 304-310
27. Pasquali R., and Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol (Oxf) 39 (1993) 1-16
28. Bringer J., Lefebvre P., Boulet F., et al. Body composition and regional fat distribution in polycystic ovarian syndrome: relationship to hormonal and metabolic profiles. Ann N Y Acad Sci 687 (1993) 115-123
29. Kirchengast S., and Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 16 (2001) 1255-1260
30. Douchi T., Ijuin H., Nakamura S., et al. Body fat distribution in women with polycystic ovary syndrome. Obstet Gynecol 86 4 Pt 1 (1995) 516-519
31. Rebuffe-Scrive M., Cullberg G., Lundberg P.A., et al. Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res 21 (1989) 391-397
32. Acien P., Quereda F., Matallin P., et al. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 72 (1999) 32-40
33. Hollmann M., Runnebaum B., and Gerhard I. Effects of weight loss on the hormonal profile in obese, infertile women. Hum Reprod 11 (1996) 1884-1891
34. Lefebvre P., Bringer J., Renard E., et al. Influences of weight, body fat patterning and nutrition on the management of PCOS. Hum Reprod 12 Suppl 1 (1997) 72-81
35. Kahn S.E., Prigeon R.L., McCulloch D.K., et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42 (1993) 1663-1672
36. Goodarzi M.O., Erickson S., Port S.C., et al. Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome. Metabolism 52 (2003) 713-719
37. Kiddy D.S., Hamilton-Fairley D., Bush A., et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36 (1992) 105-111
38. Diamond M.P., Grainger D., Diamond M.C., et al. Effects of methyltestosterone on insulin secretion and sensitivity in women. J Clin Endocrinol Metab 83 (1998) 4420-4425
39. Dunaif A., Green G., Futterweit W., et al. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 70 (1990) 699-704
40. Venkatesan A.M., Dunaif A., and Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res 56 (2001) 295-308
41. Rosenbaum D., Haber R.S., and Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol 264 2 Pt 1 (1993) E197-E202
42. Ciaraldi T.P., el-Roeiy A., Madar Z., et al. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 75 (1992) 577-583
43. Zhang L.H., Rodriguez H., Ohno S., et al. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci U S A 92 (1995) 10619-10623
44. Legro R.S., Kunselman A.R., Dodson W.C., et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 (1999) 165-169
45. Yilmaz M., Bukan N., Ersoy R., et al. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum Reprod 20 (2005) 2414-2420
46. Kaushal R., Parchure N., Bano G., et al. Insulin resistance and endothelial dysfunction in the brothers of Indian subcontinent Asian women with polycystic ovaries. Clin Endocrinol (Oxf) 60 (2004) 322-328
47. Sam S., and Dunaif A. Polycystic ovary syndrome: syndrome XX?. Trends Endocrinol Metab 14 (2003) 365-370
48. Apridonidze T., Essah P.A., Iuorno M.J., et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 1929-1935
49. Dahlgren E., Janson P.O., Johansson S., et al. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71 (1992) 599-604
50. Buggs C., and Rosenfield R.L. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 34 (2005) 677-705
51. Dahlgren E., Johansson S., Lindstedt G., et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 57 (1992) 505-513
52. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 33 (2004) 283-303
53. Ehrmann D.A., Barnes R.B., Rosenfield R.L., et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22 (1999) 141-146
54. O'Meara N. Defects in beta-cell function functional ovarian hyperandrogenism. J Clin Endocrinol Metab 76 (1993) 1241
55. Haffner S.M., Stern M.P., Hazuda H.P., et al. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA 263 (1990) 2893-2898
56. Jeppesen J., Hein H.O., Suadicani P., et al. High triglycerides and low HDL cholesterol and blood pressure and risk of ischemic heart disease. Hypertension 36 (2000) 226-232
57. Arslanian S.A., Lewy V.D., and Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 86 (2001) 66-71
58. Rexrode K.M., Hennekens C.H., Willeh W.C., et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 277 (1997) 1539
59. Talbott E., Guzick D., Clerici A., et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15 (1995) 821-826
60. Kelly C.J., Speirs A., Gould G.W., et al. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 742-746
61. Orio Jr. F., Palomba S., Cascella T., et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 4588-4593
62. Paradisi G., Steinberg H.O., Hempfling A., et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103 (2001) 1410-1415
63. Kravariti M., Naka K.K., Kalantaridou S.N., et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 5088-5095
64. Paradisi G., Steinberg H.O., Shepard M.K., et al. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 576-580
65. Diamanti-Kandarakis E., Alexandraki K., Protogerou A., et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 152 (2005) 749-756
66. Tarkun I., Arslan B.C., Canturk Z., et al. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89 (2004) 5592-5596
67. Diamanti-Kandarakis E., Spina G., Kouli C., et al. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 86 (2001) 4666-4673
68. Oliver F.J., de la Rubia G., Feener E.P., et al. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J Biol Chem 266 (1991) 23251-23256
69. Meissner M.H., Zierler B.K., Bergelin R.O., et al. Coagulation, fibrinolysis, and recanalization after acute deep venous thrombosis. J Vasc Surg 35 (2002) 278-285
70. Folsom A.R. Fibrinolytic factors and atherothrombotic events: epidemiological evidence. Ann Med 32 Suppl 1 (2000) 85-91
71. Dereli D., Ozgen G., Buyukkececi F., et al. Platelet dysfunction in lean women with polycystic ovary syndrome and association with insulin sensitivity. J Clin Endocrinol Metab 88 (2003) 2263-2268
72. Macut D., Micic D., Cvijovic G., et al. Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS). J Pediatr Endocrinol Metab 14 Suppl 5 (2001) 1353-1359 [discussion: 1365]
73. Ehrmann D.A., Schneider D.J., Sobel B.E., et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82 (1997) 2108-2116
74. Velazquez E.M., Mendoza S., Hamer T., et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43 (1994) 647-654
75. Benitez R., Sir-Petermann T., Palomino A., et al. [Prevalence of metabolic disorders among family members of patients with polycystic ovary syndrome]. Rev Med Chil 129 (2001) 707-712
76. Legro R.S., Kunselman A.R., and Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 111 (2001) 607-613
77. Sam S., Legro R.S., Bentley-Lewis R., et al. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 4797-4802
78. Anderson L.A., McTernan P.G., Harte A.L., et al. The regulation of HSL and LPL expression by DHT and flutamide in human subcutaneous adipose tissue. Diabetes Obes Metab 4 (2002) 209-213
79. Berg A.H., and Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96 (2005) 939-949
80. Carmina E., Orio F., Palomba S., et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol 152 (2005) 389-394
81. Sills E.S., Genton M.G., Perloe M., et al. Plasma homocysteine, fasting insulin, and androgen patterns among women with polycystic ovaries and infertility. J Obstet Gynaecol Res 27 (2001) 163-168
82. Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324 (1991) 1149-1155
83. Tallova J., Býcýkova M., and Hill M. Changes of plasma total homocysteine levels during the menstrual cycle. Eur J Clin Invest 129 (1999) 1041-1044
84. Yilmaz M., Biri A., Bukan N., et al. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 20 (2005) 258-263
85. Randeva H.S., Lewandowski K.C., Drzewoski J., et al. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 4496-4501
86. Vrbikova J., Bicikova M., Tallova J., et al. Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 110 (2002) 74-76
87. Ridker P. C-reactive protein and coronary heart disease. N Engl J Med 351 (2004) 295-298
88. Morin-Papunen L., Rautio K., Ruokonen A., et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 4649-4654
89. Rodin D.A., Bano G., Bland J.M., et al. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin Endocrinol (Oxf) 49 (1998) 91-99
90. Aarabi M. Coronary risk in South Asians: role of ethnicity and blood sugar. Eur J Cardiovasc Prev Rehabil 11 (2004) 389-393
91. Pierpoint T., McKeigue P.M., Isaacs A.J., et al. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51 (1998) 581-586
92. Wild S.H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 52 (2000) 595-600
93. Solomon C.G., Hu F.B., Dunaif A., et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 87 (2002) 2013-2017
94. Rexrode K.M., Manson J.E., Lee I.M., et al. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 108 (2003) 1688-1693
95. Cibula D., Cifkova R., Fanta M., et al. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 15 (2000) 785-789
96. Guzick D.S., Talbott E.O., Sutton-Tyrell K., et al. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 174 (1996) 1224
97. Talbott E.O., Zborowski J.V., Boudreaux M.Y., et al. The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 6061-6067
98. Talbott E.O., Zborowski J.V., Rager J.R., et al. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 5454-5461
99. Christian R.C., Dumesic D.A., Behrenbeck T., et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 2562-2568
100. Orio Jr. F., Palomba S., Spinelli L., et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 89 (2004) 3696-3701
101. Yarali H., Yildirir A., Aybar F., et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 76 (2001) 511-516
102. Tiras M.B., Yalcin R., Noyan V., et al. Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. Hum Reprod 14 (1999) 1949-1952
103. Wild R.A., Grubb B., Hartz A., et al. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril 54 (1990) 255-259
104. Birdsall M.A., Farquhar C.M., and White H.D. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 126 (1997) 32-35
105. Legro R.S. Polycystic ovary syndrome and cardiovascular disease: a premature association?. Endocr Rev 24 (2003) 302-312
106. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
107. Penna I.A. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. Hum Reprod 20 (2005) 2396-2401
108. Kilicdag E.B., Bagis T., Zeyneloglu H.B., et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 20 (2005) 894-899
109. Ghazeeri G., Kutteh W.H., Bryer-Ash M., et al. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 79 (2003) 562-566
110. Azziz R., Ehrmann D.A., Legro R.S., et al. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 79 (2003) 932-937
111. Sidell R.J., Cole M.A., Draper N.J., et al. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 51 (2002) 1110-1117
112. Lord J.M., Flight I.H., and Norman R.J. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 3 (2003) CD003053